-
Mashup Score: 0TPST-1120 Combo Yields Positive Activity in Hepatocellular Carcinoma - 6 month(s) ago
Adding TPST-1120 to atezolizumab and bevacizumab appears to improve progression-free survival compared with atezolizumab and bevacizumab alone in patients with hepatocellular carcinoma.
Source: Cancer NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Sara M. Tolaney, MD, MPH, discusses the evolving role of Ki-67 and circulating tumor DNA as prognostic or predictive biomarkers in breast cancer.
Source: Cancer NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Sara M. Tolaney, MD, MPH, discusses the evolving role of Ki-67 and circulating tumor DNA as prognostic or predictive biomarkers in breast cancer. #bcsm | @stolaney1 https://t.co/g21QgMuq3a
-
-
Mashup Score: 0Nivolumab/Chemo Extends Survival In Urothelial Carcinoma Sub-Study - 9 month(s) ago
The combination also demonstrates no new safety signals in patients with uresectable or metastatic disease and meets the phase 3 CheckMate-901 study’s primary survival end points.
Source: Cancer NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Patients who received nivolumab and cisplatin-based chemotherapy followed by nivolumab monotherapy experienced statistically significant benefits in OS and PFS compared with those who received standard-of-care cisplatin-based chemotherapy alone. #blcsm https://t.co/PnR9RmDqLS
-
-
Mashup Score: 3Pembrolizumab Prolong DFS Across Clear Cell RCC Disease Subgroups - 9 month(s) ago
Findings from the phase 3 KEYNOTE-564 trial support adjuvant pembrolizumab following nephrectomy as a standard-of-care treatment for patients with clear cell renal cell carcinoma.
Source: Cancer NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Adjuvant pembrolizumab improved survival vs placebo among patients with clear cell RCC regardless of disease risk or disease stage, according to data from an exploratory analysis of the phase 3 KEYNOTE-564 study. #kicsm | @DrChoueiri @kidneycan https://t.co/dowcS4uwzl
-
-
Mashup Score: 0CD19 CAR T Cell Therapy Yield High MRD-Negativity in R/R - 9 month(s) ago
Factors including measurable residual disease and CAR T-cell expansion appear to predict duration of response following JCAR014 in those with relapsed or refractory chronic lymphocytic leukemia in a phase 1/2 trial.
Source: Cancer NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
With a median follow-up of 79.6 months, the median DOR was 18.9 months (95% CI, 9.7-55.6) in those with a CR, CRi, or PR by 2018 International Workshop on Chronic Lymphocytic Leukemia at day 28 assessment. #CLL https://t.co/LxlQjGD2Ap
-
-
Mashup Score: 0Confirmatory Amivantamab NSCLC Trial Demonstrates Meaningful Benefit - 10 month(s) ago
Confirmatory results from the phase 3 PAPILLON study further support the FDA approval of amivantamab-vmjw for patients with locally advanced/metastatic EGFR exon 20 insertion–mutant non–small cell lung cancer.
Source: Cancer NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Treatment with amivantamab-vmjw plus chemotherapy yielded a clinically meaningful survival benefit over standard of care in patients with newly diagnosed, advanced or metastatic EGFR exon 20 insertion mutation–positive non–small cell lung cancer. #NSCLC https://t.co/zvCnbvVfQW https://t.co/e0EAw0TYHa
-
-
Mashup Score: 0IMDC Does Not ‘Represent Accurate Biology’ in Clear Cell RCC - 10 month(s) ago
Better biology is needed to accurately determine risk stratification features in patients with clear cell renal cell carcinoma.
Source: Cancer NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
"The IMDC classification is a fantastic prognostic indicator—good, intermediate, and poor—and it works across broad subgroups of patients; but it doesn’t represent accurate biology,” said @tompowles1 during @kidneycan. https://t.co/UC5dkMWmyp
-
-
Mashup Score: 0A2ARs Receptor Agonist Combo May be Synergistic in Clear Cell RCC - 10 month(s) ago
Clear cell renal cell carcinoma is driven by a metabolic switch that decreases VHL and increases ATP, according to an expert from Vanderbilt University Medical Center.
Source: Cancer NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
.@katy_beckermann reviews the mechanistic reasoning of using ipilimumab, nivolumab, and ciforadenant in patients advanced clear cell renal cell carcinoma in the first line setting. #kicsm | @kidneycan @VUMChealth https://t.co/TYK2jiZ0Y1
-
-
Mashup Score: 0Manuscript Guidelines | Oncology Journal - 10 month(s) ago
Home to the journal Oncology, Cancer Network provides research and opinion on the screening, early detection, diagnosis, treatment, and prevention of cancers.
Source: Cancer NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The peer-reviewed journal ONCOLOGY is looking for submissions. ONCOLOGY is free-to-submit and PubMed-indexed. View our submissions guidelines today. @DrJulieVose @HH_Oncodr https://t.co/tBrnqz8srB https://t.co/9vGCYzRe4J
-
-
Mashup Score: 0Lenvatinib/Pembrolizumab Improves Responses Vs Sunitinib in Advanced RCC - 10 month(s) ago
The improvements occur regardless of PD-L1 status among patients receiving lenvatinib plus pembrolizumab for advanced renal cell carcinoma in the phase 3 CLEAR study.
Source: Cancer NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The ORR was 71.3% (95% CI, 66.6%-76.0%) among patients receiving lenvatinib plus pembrolizumab compared with 36.7% (95% CI, 31.7%-41.7%) among those receiving sunitinib. #kicsm | @motzermd @kidneycan https://t.co/CqqZC5D9un
-
Investigators reported positive findings when combining the investigational PPAR⍺ antagonist TPST-1120 with atezolizumab and bevacizumab as a frontline treatment for patients with hepatocellular carcinoma. #gicsm https://t.co/dOiaoKZAkd